Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Category: #health  By Paroma Bhattacharya  Date: 2019-10-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from Phase ½ results were presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

MRTX849 has exhibited clinical activity in patients with solid tumors with KRAS G12C mutations, colorectal cancer and non-small cell lung cancer. As the trial continues to enroll patients, maximum tolerated dose is expected to be established soon.

Charles M. Baum, President and CEO, Mirati Therapeutics has been reported to say that patients who suffer from KRAS G12C mutation in their tumors often endure poor prognosis as their ailment is resistant to standard care and targeted therapeutics have not yet been developed for them.

He added that Phase 1/2 trial of MRTX849 has demonstrated the safety data and efficacy required for an effective KRAS therapy. MRTX849 is being tested in a number of patients suffering from KRAS G12C mutated cancers with the hope of soon being able to provide them with much needed therapy.

Of the 17 patients enrolled in the first-in-human ongoing Phase ½ of MRTX849, 10 patients are suffering from non-small cell lung cancer, 4 patients are affected with colorectal cancer and 3 have other tumor types. Trial objectives include pharmacodynamics, tolerability, pharmacokinetics and safety of the therapy.

Pasi A. Jänne, MRTX849-001 investigator and Director of The Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute said that finding a therapeutic approach for KRAS mutations would have tremendous clinical impact for cancer patients as these mutations are the most common oncogenic alteration.

Cancer Discovery, which is a journal of the American Association of Cancer Researchers and publishes major advances in research and clinical trials also published an article about MRTX849. The article on the preclinical studies of MRTX849 describes the challenging research path that was undertaken to develop a therapy that directly targets KRAS.

 

Source Credit: https://ir.mirati.com/news-releases/news-details/2019/Mirati-Therapeutics-Presents-First-Clinical-Data-Of-Phase-12-Trial-Of-MRTX849-At-The-2019-AACR-NCI-EORTC-International-Conference-On-Molecular-Targets-And-Cancer-Therapeutics/default.aspx



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...

Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
By Paroma Bhattacharya

With growing occurrence of liver cancer cases across the globe, the need to find a solution to the ailment is rising steadily among global biotechnology and pharmaceutical firms. Various clinical trials and studies are...